Physicians Must Select High-Risk Patients for ARPI Therapy: CancerNetwork
Physicians treating localized prostate cancer must carefully select patients with higher-volume and high-grade disease for perioperative androgen receptor pathway inhibitors to see meaningful clinical benefits, CancerNetwork reported. Localized prostate cancer spans a wide spectrum of aggressiveness, both histologically and genomically, ranging from low to intermediate and high risk. Even within the nonmetastatic high-risk cohort, patients … Read more